Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Armo BioSciences Inc.

Division of Eli Lilly & Co.
www.armobio.com

Latest From Armo BioSciences Inc.

Lartruvo Phase III Fail Rocks Lilly Oncology Plans

It looks like the end for Latruvo after a late-stage trial in soft tissue sarcoma patients did not confirm the overall survival benefit seen in the Phase II study that saw the Lilly drug get a speedy approval from the FDA and the EMA in 2016.

Cancer Clinical Trials

How Lilly Aims To Make Sure Good Drugs Don't Get Lost In Translation

SVP/CSO Daniel Skovronsky says the company has invested in technology and biotech-like teams to speed up the process of translating targets identified in house into human data for novel drugs.

Business Strategies Research and Development Strategies

Lift-Off For Lilly In Cancer Genetics With Loxo Buy

The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.

M & A Cancer

Lilly's New Year Resolution: Make New Launches Into Blockbusters

Lilly laid out its 2019 financial forecast and commercial and R&D goals during an investor event in New York. While there were no big surprises, the company updated investors on important catalysts in diabetes, immunology, oncology and pain.

Business Strategies Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • Peter Van Vlasselaer, PhD, Pres. & CEO
    Martin Oft, MD, VP, Preclinical & Clin. Dev.
    Joseph Leveque, MD, CMO
  • Contact Info
  • Armo BioSciences Inc.
    575 Chesapeake Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register